Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free NAVB Stock Alerts

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
Compare

NAVB vs. CLVR, SCPS, EVLO, GNCA, and PXMD

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? Navidea Biopharmaceuticals's main competitors and comparable companies include Clever Leaves (CLVR), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCA), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Navidea Biopharmaceuticals Neutral

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Clever Leaves beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Evelo Biosciences?

Navidea Biopharmaceuticals (NYSE:NAVB) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Evelo Biosciences N/A N/A N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Evelo Biosciences Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Evelo Biosciences on 5 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

Export
MetricNavidea BiopharmaceuticalsPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$10K$11.89B$7.06B$24.33B
Dividend YieldN/A2.70%2.57%3.68%
P/E Ratio0.00775.15269.0630.78
Price / SalesN/A741.16592.9621.24
Price / CashN/A66.4570.4832.80
Price / BookN/A11.6012.916.82
Net Income-$15.18M$2.77B$3.45B$1.06B

Navidea Biopharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
CLVR
Clever Leaves
N/A$0.01
flat		N/AN/A$18K$17.42MN/A560
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A-66.7%$17KN/AN/A9
EVLO
Evelo Biosciences
N/AN/AN/AN/A$6KN/AN/A120
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel